Lipo-Group Research Constellation (LGRC)
The final goal of our research activity is the discovery of biomarkers and therapeutic targets for the diagnosis and treatment of cardiometabolic diseases by increasing the knowledge on lipoprotein, lipid, and carbohydrate metabolism.
Cardiometabolic diseases (atherosclerotic cardiovascular disease, diabetes mellitus type II, and non alcoholic fatty liver disease) are the first cause of mortality and hospitalization worldwide. Epidemiological studies have shown the complexity of cardiometabolic diseases identifying a large number of risk factors.
The liver is a fundamental organ for the regulation of lipoprotein, lipid, and carbohydrate metabolism, being the center of the physiologic processes that maintain carbohydrate and lipid homehostasis.
The Lipo-Group Research Constellation (LGRC), led by Paolo Parini and Mats Eriksson, merges the efforts and background from various medical specialties (internal medicine, hepatology, gastroenterology, and endocrinology) with the science from genetics, clinical biochemistry, and molecular biology.
The multi-disciplinary expertise and the deep knowledge of human physiology allow LGRC to drive translational pre-clinical and clinical research activities and to intergrated the results into models and hypotheses that are translatable to human condition.
One example of the many research projects that LGRC drives is HUMAN:
HUMAN (Health and the Understanding of Metabolism, Aging and Nutrition, http://www.fp7human.eu) is a consortium with a EU-funded research project that started in October 2013. HUMAN aims to study the function of genetic risk variant associated to metabolic diseases by employing a unique translational model of human glucose and lipid metabolism: mouse with humanised liver and pancreas. Paolo Parini is the coordinator of HUMAN, and with several member of the LGRC actively contribute with a research activity aimed to: 1) characterize the metabolic phenotype of the humanized mice produced within the consortium, specifically by determining whether the liver humanized mouse model recreates the metabolic characteristics of a human liver and by characterizing changes in clinical metabolic parameters of disease and aging; 2) investigate sex related differences in hepatic lipid and lipoprotein metabolism of the liver humanized mice by repopulation of male or female animals with hepatocytes from disease-free women or men; 3) investigate the humanized phenotype of liver-targeted pharmacology, using the oxysterol receptor LXR as a model system; 4) use CRISPR/Cas9 to genetically modify iPSCs carrying risk/protective alleles.
LGRC also offers an unique competence and technological platform to drive studies for: a) pharmacological target validation, b) evaluation of lipid and glucose metabolism, c) detailed characterization of lipoprotein composition, structure and functions
Please contact us for more informations and possible future collaborations!
Research group leader
- CRISPR Cas9 gene editing, Lipoproteins isolation and characterization (i.e. D2O-sucrose and KBr gradient ultracentrifugation, native and denatured polyacrylamide gel electrophoresis, size exclusion chromatography, serum and HDL cholesterol efflux capacity measurement, lipoprotein binding to arterial proteoglycans), extraction and quantification of lipids and glycogen in cells and tissues, RNA-DNA extraction and purification, enzymatic and ELISA assays, gene expression, protein expression, cloning, mutagenesis, cell culture, transfections.
- Work with animal models: quantification of macrophagic reverse cholesterol transport (RCT) in- vivo, glucose and insulin tolerance test, evaluation of atherosclerosis development in the aorta, mouse genotyping, tissue and organ collection, gavage, tail vein injection
EU Fp7 HUMAN (www.fp7human.eu), Swedish Heart-Lung foundation, AstraZeneca, Swedish Research Council, ALF, SSMF, Moderna
BMA undergraduate program, postgraduate courses, medical program, bachelor programs in Biomedicine and Nutrition